Improvements in our understanding of the human genome and molecular medicine continue to facilitate remarkable breakthroughs in both research and clinical practice. But even with today’s novel methodologies, accurate and sensitive analysis of certain genomic targets remains a challenge for laboratories.
Whether the challenge is simply having a robust and reliable solution to measuring repeat sequences in DMPK (myotonic dystrophy type 1), or to provide a more efficient & cost effective NGS solution enabling parallel DNA and RNA workflows, or the need for an ultra-sensitive assay for the measurement of rare BCR-ABL p190 transcripts, Asuragen’s simple-to-adopt systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms.
Meet the Asuragen team and learn more about our broad and growing portfolio of clinical research and diagnostic kits for use across multiple genetics and oncology applications.
Next-Generation Genotyping of Unstable DNA: Expanding AmplideX® PCR Technology Across Neurodegenerative and Neurodevelopmental Disorders
Thomas W. Prior, Ph.D., FACMG, Professor of Pathology and Neurology, Director of Molecular Pathology, The Ohio State University Wexner Medical Center
Andrew Hadd, Ph.D., Director of Research and Development, Asuragen, Inc.
Structural variants and repeat sequences comprise half of the human genome and are hallmarks of many neurodegenerative and neurodevelopmental disorders. Repetitive DNA has long challenged conventional diagnostic approaches and stifled scientific and clinical research. In this workshop, we will demonstrate how AmplideX® technology can be expanded to new, easy-to-use assay kits to characterize repeat loci across the genome. We will review several complex gene sequences implicated in neurological disorders, the difficulties they present in the laboratory, and how Asuragen is making analysis of these genes easier than ever.
Wednesday, November 15
12:00 – 12:50 pm
Our SVP R&D, Gary Latham, Ph.D., will be presenting on our behalf at ThermoFisher’s corporate workshop!
Introducing the SeqStudio™ Genetic Analyzer: Expert Results Simplified
Gary Latham, Ph.D., Senior Vice President of Research and Development, Asuragen, Inc.
Jennifer Holbrook, B.S., Assistant Director, Biomolecular Core Laboratory at Nemours/A.I. duPont Hospital for Children
Wednesday, November 15
11:00 – 11:50 am
Saturday, November 18
9:45 – 10:45 am
ST115: An efficient and ultra-sensitive next-generation sequencing method for profiling circulating tumor DNA
Presented by Brian Haynes, Ph.D.
ST109: A modular next-generation sequencing technology that couples the detection of RNA structural variants with DNA mutations in lung cancer
Presented by Richard Blidner, Ph.D.
H55: BCR-ABL1 minor breakpoint monitoring using an analytically validated multiplex assay
Presented by Justin Brown, Ph.D.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.